

Major participation by CytoTools AG and other existing shareholders in capital increase of successful subsidiary DermaTools Biotech GmbH and consequent securing of financing for all further clinical developments

- DermaTools receives around EUR 5.2 million of fresh equity
- CytoTools AG and four existing shareholders subscribe for new shares
- Funds to be used to finance and expand various clinical studies

Darmstadt, May 29, 2013 – An increase in share capital to EUR 127,500 has just been approved unanimously at the shareholder meeting of DermaTools Biotech GmbH. CytoTools AG and four existing shareholders have provided a total of EUR 5.2 million of new equity as part of this capital increase. This allows all of DermaTools' further current clinical plans to be implemented. As planned, CytoTools AG extended to its subsidiary around EUR 2 million of the funds that it raised from its own capital increase in March 2013, thereby maintaining an almost unchanged interest in DermaTools Biotech GmbH. This extensive strengthening of liquidity allows CytoTools AG to support its subsidiary's successful clinical developments.

Above all, the funds raised through the capital measure can be deployed for the further clinical testing of the DermaPro[®] substance, and to finalise certification of the urological medical product Utisept[®]. DermaTools can consequently expand clinical studies on the DermaPro[®] to two further indications, and conclude its decisive Phase III studies in Europe without further need for external capital.

"We regard it as a major proof of confidence that other existing shareholders have also made significant use of their subscription rights in this capitalisation round. It is testimony to the far-reaching clinical development progress that DermaTools has achieved in Europe," commented Dr. Mark-Andre Freyberg, CEO of CytoTools AG.

The final results of the Indian registration trial for the DermaPro[®] substance of licence partner Centaur Pharmaceuticals are also expected in the next few weeks. "This development represents a decisive milestone for DermaTools. With the expected results, the last hurdle before the first registration of a substance developed by CytoTools will have been crossed. This would represent a real breakthrough for a German biotech company," noted Dr. Freyberg by way of conclusion.

PRESS RELEASE



This release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: around 58% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
64285 Darmstadt, Germany
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

Press contact:

cometis AG
Ulrich Wiehle
Unter den Eichen 7
65195 Wiesbaden, Germany
Tel.: +49-611-205855-11
Fax: +49-611-205855-66
E-Mail: wiehle@cometis.de